inclusion criteria: * healthy adult volunteers ages 18 years and above, who are able to provide written informed consent and willing to allow storage and future use of samples for sars-cov-2 related research. * women of childbearing potential (wocbp) must have negative serum or urine pregnancy on each day of vaccine administration. * males and women of childbearing potential must agree to take appropriate precautions to avoid pregnancy during treatment and through 180 days after last dose of ip.

inclusion criteria: * healthy adult volunteers ages 18 years and above, who are able to provide written informed consent and willing to allow storage and future use of samples for sars-cov-2 related research. * women of childbearing potential (wocbp) must have negative serum or urine pregnancy on each day of vaccine administration. * males and women of childbearing potential must agree to take appropriate precautions to avoid pregnancy during treatment and through 180 days after last dose of ip.

inclusion criteria: - healthy adult volunteers ages 18 years and above, who are able to provide written informed consent and willing to allow storage and future use of samples for sars-cov-2 related research. - women of childbearing potential (wocbp) must have negative serum or urine pregnancy on each day of vaccine administration. - males and women of childbearing potential must agree to take appropriate precautions to avoid pregnancy during treatment and through 180 days after last dose of ip.

inclusion criteria: - healthy adult volunteers ages 18 years and above, who are able to provide written informed consent and willing to allow storage and future use of samples for sars-cov-2 related research. - women of childbearing potential (wocbp) must have negative serum or urine pregnancy on each day of vaccine administration. - males and women of childbearing potential must agree to take appropriate precautions to avoid pregnancy during treatment and through 180 days after last dose of ip.